Recent Performance Snapshot

Innospec (IOSP) has drawn investor attention after a weak month, with the stock showing a 20.46% decline over that period and a 12.78% decline over the past 3 months.

Set against a 1 day share price return of 1.10%, the recent 30 day share price return of 20.46% and 1 year total shareholder return of 28.70% suggest momentum has been fading over both shorter and longer periods.

If you are reassessing your portfolio after these moves, it can be useful to see what else the market is pricing in and compare Innospec with 20 top founder-led companies

With Innospec trading at US$68.87 against an analyst price target of US$99.33 and an indicated intrinsic discount of around 15%, you have to ask: is this a genuine value opening, or is the market already pricing in future growth?

Most Popular Narrative: 30.7% Undervalued

With Innospec last closing at $68.87 against a narrative fair value of $99.33, the most followed view sees a sizeable gap between price and projected fundamentals.

The analysts have a consensus price target of $115.0 for Innospec based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analyst's consensus, you would need to believe that by 2028, revenues will be $2.1 billion, earnings will come to $457.7 million, and it would be trading on a PE ratio of 7.4x, assuming you use a discount rate of 7.3%.

The fair value story rests on a specific mix of revenue growth, thicker margins and a future earnings multiple that looks very different from today. Want to see how those pieces fit together and what assumptions drive that $99.33 figure at a 7.37% discount rate? The full narrative lays out the numbers behind that call in plain sight.

Result: Fair Value of $99.33 (UNDERVALUED)

However, this story can change quickly if margin pressure in Performance Chemicals persists, or if ongoing raw material cost swings squeeze profitability more than expected.

Next Steps

If this mix of caution and optimism has you on the fence, now is a good time to review the details yourself and stress test the assumptions. A simple place to start is by weighing the potential upside against the company specific positives highlighted in our 6 key rewards

Looking for more investment ideas?

If Innospec is only one piece of your watchlist, now is the moment to widen your search and line up a few more high conviction candidates.

• Target income potential with companies that currently offer robust payouts by scanning 15 dividend fortresses tailored for yield focused investors.
• Hunt for quality businesses that the market may be pricing cautiously using the screener containing 27 high quality undiscovered gems before others catch on.
• Prioritise resilience and support a more defensive approach by filtering for companies in the 76 resilient stocks with low risk scores that score well on risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.